検索結果

ts in Japan is increasing. Senju will work diligently to provide new treatment options for patients suffering from allergic conjunctivitis and advance the development of the drug toward marketing appr...

ts in Japan is increasing. Senju will work diligently to provide new treatment options for patients suffering from allergic conjunctivitis and advance the development of the drug toward marketing appr...

Product Development Policy | Research & Development | SENJU Pharmaceutica

atter condition is rare in Japan and generally known as a rare disease, yet there are many patients suffering from it worldwide and it is known as the most common hereditary corneal diseasesup#5,6. Cu...

ctivity. We sincerely hope that Avarept® will contribute to improving symptoms in the many patients suffering from DED.” Senju is committed to contributing to treatments that improve patients’ quality...

ctivity. We sincerely hope that Avarept® will contribute to improving symptoms in the many patients suffering from DED.” Senju is committed to contributing to treatments that improve patients’ quality...